加载中
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
收盘时
US$2.325
−US$0.095 · -3.93%
盘后
US$2.3409
+US$0.0159 · +0.68%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
日内区间
当前US$2.325
52周区间
当前US$2.325
盘中时间采用ET。市场数据可能有所延迟。
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
日内区间
当前US$2.325
52周区间
当前US$2.325
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7620.1万 USD | 1.38亿 USD | 1.01亿 USD | 5316.3万 USD | 3731.2万 USD |
| 毛利 | 7620.1万 USD | 1.38亿 USD | 1.01亿 USD | 5316.3万 USD | 3731.2万 USD |
| 研究与开发 | 6872.8万 USD | 8338.2万 USD | 7768万 USD | 1.12亿 USD | 1.14亿 USD |
| 销售、一般及管理费用 | 2983.7万 USD | 2972.6万 USD | 3001.8万 USD | 4284.9万 USD | 3916万 USD |
| 营业费用 | 9856.5万 USD | 1.13亿 USD | 1.08亿 USD | 1.54亿 USD | 1.53亿 USD |
| 利息收入 | 520.6万 USD | 713.6万 USD | 983.7万 USD | 167.8万 USD | 25.5万 USD |
| 折旧和摊销 | 137.6万 USD | 176.8万 USD | 217.5万 USD | 244.3万 USD | 270.6万 USD |
| 营业利润 | −2236.4万 USD | 2499.5万 USD | −648.4万 USD | −1.01亿 USD | −1.16亿 USD |
| 净利润 | −1736.8万 USD | 3186.9万 USD | −56.9万 USD | −9931.7万 USD | −1.16亿 USD |
公司数据更新于 2026年10月14日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2093.41万0.00%2.3万亿 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI1281.35万0.12%103.03亿 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM1170.03万0.02%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF702.85万0.01%954亿 USD0.05%US$232.54-0.42%
iShares Biotechnology ETFIBB359.2万0.03%107.38亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO343.53万0.02%180亿 USD0.06%US$111.77-0.45%
iShares Russell 2000 Growth ETFIWO232.39万0.02%137.9亿 USD0.24%US$351.1-0.74%
iShares Russell 2000 Value ETFIWN194.78万0.01%137.52亿 USD0.24%US$210.99-0.05%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Russell 2000 Value ETFIWNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
